Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Stakeholder Opinions - Renal Anemia Early diagnosis and management of anemia - reducing costs and improving the outcomes in chronic kidney disease (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 10 Apr 2009
- Report Title: Stakeholder Opinions - Renal Anemia Early diagnosis and management of anemia - reducing costs and improving the outcomes in chronic kidney disease
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 83
Introduction
The diagnosis of renal anemia is routinely performed and relatively straightforward, while treatment with highly effective erythropoietin-stimulating agents is widely available in all major markets. However, the extremely high cost of treatment prevents many healthcare providers from delivering this treatment to all eligible patients.
Scope
*What are the current definitions, pathophysiological stages and the classification of renal anemia?
*What are the currently available diagnostic methods, the issues and the unmet needs in diagnosis and early detection of renal anemia?
*What is the current state of pharmacological management, available treatment approaches in renal anemia, unmet needs and future trends?
*What are the current issues and the commercial landscape of renal anemia marketplace?
Highlights
In Europe, biogeneric epoetins were expected to address the cost issue, however, so far they have not been particularly well received. This seems to be mostly due to physician conservatism and the fear of poor generic drug quality with attendant higher risk of side effects. Only Germany has displayed any degree of enthusiasm for biogenerics.
A number of large clinical trials, such as CHOIR and CREATE, have demonstrated some controversial results with regards to the relative inefficiency of higher hemoglobin targets. This has encouraged healthcare providers to be conservative in the choice of epoetin therapy creating an additional barrier to epoetin revenue growth.
New epoetin drug therapies predominantly address the length of drug action, allowing for less frequent administration, but unfortunately they provide neither substantial superiority nor significant reduction of costs. In addition, a very small upcoming pipeline does not yet promise any advancement in the area of superiority or reduction of cost.
Reasons to Purchase
*Understand current definitions, diagnostic methods and treatment approaches in renal anemia
*Current challenges and future opportunities in renal anemia management
*Differences, advantages and disadvantages of pharmacological disease management
The diagnosis of renal anemia is routinely performed and relatively straightforward, while treatment with highly effective erythropoietin-stimulating agents is widely available in all major markets. However, the extremely high cost of treatment prevents many healthcare providers from delivering this treatment to all eligible patients.
Scope
*What are the current definitions, pathophysiological stages and the classification of renal anemia?
*What are the currently available diagnostic methods, the issues and the unmet needs in diagnosis and early detection of renal anemia?
*What is the current state of pharmacological management, available treatment approaches in renal anemia, unmet needs and future trends?
*What are the current issues and the commercial landscape of renal anemia marketplace?
Highlights
In Europe, biogeneric epoetins were expected to address the cost issue, however, so far they have not been particularly well received. This seems to be mostly due to physician conservatism and the fear of poor generic drug quality with attendant higher risk of side effects. Only Germany has displayed any degree of enthusiasm for biogenerics.
A number of large clinical trials, such as CHOIR and CREATE, have demonstrated some controversial results with regards to the relative inefficiency of higher hemoglobin targets. This has encouraged healthcare providers to be conservative in the choice of epoetin therapy creating an additional barrier to epoetin revenue growth.
New epoetin drug therapies predominantly address the length of drug action, allowing for less frequent administration, but unfortunately they provide neither substantial superiority nor significant reduction of costs. In addition, a very small upcoming pipeline does not yet promise any advancement in the area of superiority or reduction of cost.
Reasons to Purchase
*Understand current definitions, diagnostic methods and treatment approaches in renal anemia
*Current challenges and future opportunities in renal anemia management
*Differences, advantages and disadvantages of pharmacological disease management
Browse over 450,000 market research reports, company profile reports and company financials. Search by industry sector, or simply search market research reports or company profiles by keyword. Companiesandmarkets.com contains one of the world's largest collections of market research reports and company profiles from leading global market research report publishers and analysts. Global brands rely on companiesandmarkets.com for their strategic market research needs.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card, Credit Card, or by Invoice.
Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
